WuXi Biologics Secures South Korea GMP Nod for Bispecific Manufacturing

Event summary

  • WuXi Biologics received GMP certification from the South Korea MFDS for three facilities (MFG5, DP2, DPPC) in Wuxi.
  • The certification enables commercial manufacturing of a bispecific antibody for biliary tract cancer treatment.
  • The inspection found no critical or major findings, highlighting WuXi Biologics’ quality systems.
  • As of December 2025, WuXi Biologics has passed 46 regulatory inspections and secured 136 facility license approvals.
  • The company boasts a 100% pass rate for FDA Pre-License Inspections (PLI).

The big picture

This GMP certification expands WuXi Biologics’ manufacturing footprint in Asia, a region experiencing rapid growth in biopharmaceutical development. The approval for bispecific antibodies underscores the company’s focus on complex biologics, a high-growth area within the industry. Securing MFDS approval demonstrates WuXi Biologics’ ability to navigate increasingly stringent regulatory environments and positions them to capture a larger share of the global contract manufacturing market.

What we're watching

Geopolitical Risk
The reliance on Chinese manufacturing facilities for critical drug components introduces geopolitical risk, and future regulatory shifts in China could impact WuXi Biologics' operations and certifications.
Competitive Landscape
Increased competition among CRDMOs will likely put pressure on pricing and margins, requiring WuXi Biologics to continually innovate and demonstrate value to clients.
Client Concentration
The success of this certification is tied to a specific bispecific antibody; the company's future revenue will depend on the commercial success of that product and the continued expansion of its client base.

Related topics

Regulatory Approval